QRP Research ARA-290 (Cibinetide) 10mg
 
ARA-290, also known as Cibinetide or pHBSP (Pyroglutamate Helix B Surface Peptide), is a synthetic 11-amino-acid peptide derived from the three-dimensional structure of the helix B surface region of erythropoietin (EPO).
ARA-290 was developed as a research compound to investigate selected non-erythropoietic signalling mechanisms associated with erythropoietin, while remaining structurally and functionally distinct from full-length EPO.
A major area of scientific interest surrounding ARA-290 is the Innate Repair Receptor (IRR), described in the research literature as a heteromeric receptor complex involving the erythropoietin receptor (EPOR) and the beta-common receptor CD131 (βcR).
Unlike conventional erythropoietin signalling through the EPOR homodimer, ARA-290 has been investigated for its interaction with this alternative receptor pathway without stimulating the classical erythropoietic pathway responsible for red blood cell production.
QRP Research ARA-290 10mg is supplied as a lyophilised research peptide intended exclusively for controlled laboratory, analytical and scientific investigation.
Key Research Areas
ARA-290 has been investigated experimentally in relation to:
Innate Repair Receptor (IRR) signalling
EPOR / CD131-associated pathways
Erythropoietin-derived peptide biology
Cellular stress-response mechanisms
Inflammatory signalling pathways
Cytokine-associated cellular signalling
Cell survival and apoptosis-related mechanisms
Tissue-response signalling
Neuronal and peripheral nerve research
Immune-cell signalling
JAK-associated intracellular pathways
Cellular responses to injury and metabolic stress
A particularly important characteristic of ARA-290 is that it was designed from the solvent-exposed surface of erythropoietin helix B, rather than as a shortened conventional EPO molecule.
This structural approach has made ARA-290 an important experimental model for investigating whether non-haematopoietic EPO-associated signalling can be studied independently from classical erythropoiesis.
Research has also examined ARA-290 in experimental models involving inflammatory responses, neuronal signalling, metabolic stress and cellular injury, providing several areas of interest for molecular and cellular research.
Research findings involving ARA-290 should not be interpreted as evidence of established neuroprotective, anti-inflammatory, regenerative, pain-relieving, therapeutic or other clinical effects of this research product.
Product Specification
Compound: ARA-290
Alternative Name: Cibinetide
Research Names: pHBSP / Pyroglutamate Helix B Surface Peptide
Compound Type: Synthetic EPO-derived peptide
Peptide Length: 11 amino acids
Structural Origin: Helix B surface region of erythropoietin
Primary Research Target: Innate Repair Receptor (IRR)
Associated Receptor Components: EPOR / CD131 (βcR)
Form: Lyophilised peptide
Quantity: 10mg per vial
Brand: QRP Research
Application: Laboratory and scientific research
Why QRP Research?
QRP Research supplies specialist research materials with an emphasis on quality, consistency and traceability. Products are securely packaged and clearly identified for their intended laboratory application.
Storage
Store in a cool, dry and dark environment, protected from excessive heat, direct light and moisture.
Appropriate laboratory storage procedures should be followed to preserve the stability and integrity of the research material.
Research Use Notice
FOR RESEARCH USE ONLY.
This product is supplied exclusively for laboratory, analytical and scientific research.
NOT for human consumption or administration.
NOT for animal consumption or administration.
NOT a medicine, food supplement or cosmetic product.
NOT intended to diagnose, treat, cure or prevent any disease.
No human dosing or administration instructions are provided.
Intended to be handled only by appropriately qualified researchers or laboratory professionals.
QRP Research ARA-290 (Cibinetide) 10mg is supplied strictly as a research material for non-clinical laboratory investigation.